Please assess the completion status of the following clinical trial:

Trial Title: Predictors of Tumor Response and of Radiation Therapy Side Effects in Patients With Gastrointestinal Cancers

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
* INCLUSION CRITERIA:~* Age greater than or equal to 18 years.~* Histologically confirmed carcinoma of the gastrointestinal tract (esophagus, stomach, pancreas, bile duct, rectum).~* Treatment plan includes radiotherapy to the site of the gastrointestinal malignancy on an National Cancer Institute (NCI) protocol.~* Paraffin embedded tumor tissue from biopsy or surgery adequate in amount to perform polymerase chain reaction (PCR) and methylation specific PCR or willingness to undergo re-biopsy.~EXCLUSION CRITERIA:~* Inability to provide informed consent.~* Patients who have a history of prior therapeutic radiation.~* Patients with evidence of distant metastases on initial staging evaluation.~* Patients with other cancers excluding non-melanomatous skin cancers or carcinoma in situ.~* History of inflammatory bowel disease.~* History of collagen vascular disease or disease of altered collagen metabolism (end stage renal disease or hepatic fibrosis due to chronic hepatitis).~* History of hypersensitivity to radiation or a history of a disease which results in mucosal or other hypersensitivity to radiation (Ataxia-Telangiectasia, Bloom's Syndrome, Human Immunodeficiency Virus, Fanconi anemia, nevoid basal cell carcinoma syndrome, Li-Fraumeni syndrome, and Nijmegen breakage syndrome).~* Inability to return for follow-up visits.~* Patients who have previously received or are currently receiving MDX-101 (ipilimumab).~* Diagnosis of human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Markers of Tumor Burden and Radiation Toxicity (Type: None): Serum, plasma, urine, and stool samples will be collected prior to radiotherapy for participants with gastrointestinal malignancies.

Based on this trial design, predict the completion outcome and termination type (if applicable).